CStone Pharmaceuticals Management
Management criteria checks 3/4
CStone Pharmaceuticals' CEO is Jason Yang, appointed in Aug 2022, has a tenure of 2.25 years. total yearly compensation is CN¥57.81M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 1.29% of the company’s shares, worth €4.05M. The average tenure of the management team and the board of directors is 2 years and 5.7 years respectively.
Key information
Jason Yang
Chief executive officer
CN¥57.8m
Total compensation
| CEO salary percentage | 8.3% |
| CEO tenure | 2.3yrs |
| CEO ownership | 1.3% |
| Management average tenure | 2yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥142m |
| Mar 31 2024 | n/a | n/a | -CN¥255m |
| Dec 31 2023 | CN¥58m | CN¥5m | -CN¥367m |
| Sep 30 2023 | n/a | n/a | -CN¥559m |
| Jun 30 2023 | n/a | n/a | -CN¥750m |
| Mar 31 2023 | n/a | n/a | -CN¥827m |
| Dec 31 2022 | CN¥62m | CN¥3m | -CN¥903m |
Compensation vs Market: Jason's total compensation ($USD7.99M) is above average for companies of similar size in the German market ($USD1.03M).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
CEO
Jason Yang (60 yo)
2.3yrs
Tenure
CN¥57,808,000
Compensation
Dr. Jianxin Yang, M.D., Ph D., also known as Jason, serves as President of R&D of CStone Pharmaceuticals since 2024 and was its Senior Vice President and Chief Medical Officer December 2016 until 2024. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President of R&D and Executive Director | 2.3yrs | CN¥57.81m | 1.29% € 4.0m | |
| CFO & Joint Company Secretary | 1.8yrs | no data | no data | |
| Senior VP & Chief Operating Officer | less than a year | no data | no data | |
| Senior VP & Chief Scientific Officer | no data | no data | no data | |
| Chief Commercial & Strategic Officer | 3.5yrs | no data | no data | |
| Senior Vice President of Product Development | 3.5yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
2.0yrs
Average Tenure
49yo
Average Age
Experienced Management: PH4's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President of R&D and Executive Director | no data | CN¥57.81m | 1.29% € 4.0m | |
| Member of Scientific Advisory Board | 5.7yrs | no data | no data | |
| Independent Non-Executive Director | 5.8yrs | CN¥282.00k | no data | |
| Non-Executive Director | 4yrs | no data | no data | |
| Independent Non-Executive Director | 5.8yrs | CN¥711.00k | no data | |
| Non Executive Director | 2.9yrs | CN¥415.00k | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Independent Non-Executive Director | 5.8yrs | CN¥282.00k | no data | |
| Non-Executive Chairman | 8.9yrs | no data | no data | |
| Non-Executive Director | 3.3yrs | no data | 0.072% € 225.5k |
5.7yrs
Average Tenure
61yo
Average Age
Experienced Board: PH4's board of directors are considered experienced (5.7 years average tenure).